Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results

INTRODUCTION/OBJECTIVES: To evaluate the three-year efficacy and safety of ixekizumab with and without concomitant conventional synthetic disease-modifying antirheumatic drug (csDMARD) use in patients with active psoriatic arthritis (PsA). METHOD: Patients with PsA who were biologic-naïve (SPIRIT-P1...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C., Mease, Philip, Kronbergs, Andris, Helt, Cameron, Sandoval, David, Park, So Young, Combe, Bernard, Nash, Peter, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485169/
https://www.ncbi.nlm.nih.gov/pubmed/35674861
http://dx.doi.org/10.1007/s10067-022-06218-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485169/
https://www.ncbi.nlm.nih.gov/pubmed/35674861
http://dx.doi.org/10.1007/s10067-022-06218-8

Ejemplares similares